InflaRx N.V.
IFRX · XNASCIK 1708688fmd_1BA3CB5N1ZZR546TFF50FPBDFZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 18 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Cost of revenue | – | – | – | – | – | – | – | 1 | 3 | 7 |
| Gross profit | (7) | (20) | (38) | – | – | – | – | (0) | (3) | (7) |
| Research and development | 5 | 14 | 25 | 45 | 26 | 36 | 38 | 41 | 35 | 26 |
| Selling, general and administrative | 2 | 5 | 13 | 13 | 8 | 0 | 0 | 0 | 0 | 0 |
| Operating income | – | – | – | – | – | (48) | (32) | (45) | – | – |
| Interest expense | 2 | 5 | 0 | (0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (9) | (24) | (30) | (53) | (34) | (46) | (29) | (43) | (46) | (46) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | 0 | 0 |
| Net income from continuing operations | (7) | (19) | (30) | (53) | (34) | (46) | – | – | (46) | (46) |
| Net income | (9) | (24) | (30) | (53) | (34) | (46) | (29) | (43) | (46) | (46) |